HPSE and chondrogenic neoplasm: The recent report showing that roneparstat inhibits chondrogenesis and chondrogenic marker gene expression in mesenchymal cells from mouse embryo [52] suggests a potential therapeutic interest for the drug in treatments of hereditary multiple exostoses, benign pediatric cartilaginous tumors overexpressing heparanase.